24/7 Market News Snapshot 12 September, 2025 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)
DENVER, Colo., 12 September, 2025 (www.247marketnews.com) – (NASDAQ:PLRZ) are discussed in this article.
Polyrizon Ltd. (NASDAQ:PLRZ) has captured significant attention in the financial markets with its stock soaring 59.39% during the pre-market session, now trading at approximately $1.558. This substantial increase from the previous closing price of $0.978 is accompanied by a notable trading volume of 5.90 million shares, indicating robust investor enthusiasm and confidence. Analysts suggest that the favorable technical indicators may signal further upward momentum for the stock, positioning Polyrizon as an attractive opportunity for investors looking to benefit from its current trajectory.
Concurrently, Polyrizon has announced promising preclinical results for its innovative PL-14 Allergy Blocker, developed as part of its proprietary Capture & Contain (C&C) platform. This breakthrough product aims to address allergic rhinitis through its unique barrier-forming mechanism. Recent studies, conducted in collaboration with a leading university, have demonstrated that PL-14 achieves over 60% deposition in the nasal vestibule, a critical area where allergens first make contact. This targeted delivery reinforces the product’s potential to act as a protective barrier against allergens, thereby mitigating immune responses associated with allergies.
CEO Tomer Izraeli emphasized the significance of these findings, stating that the results bolster Polyrizon’s objective of establishing an effective physical barrier at the point of allergen exposure. Given the growing global market for allergen blockers, projected to reach USD 0.21 billion by 2033, the PL-14 Allergy Blocker is positioned as a pioneering solution in the realm of allergy prevention. With favorable sprayability and coverage demonstrated in preclinical tests, Polyrizon is focused on further validating its product and advancing toward clinical trials to enhance the quality of life for those suffering from allergic conditions.